Last updated: July 31, 2025
Introduction
The Russian Federation patent RU2763796, granted in 2022, pertains to a novel pharmaceutical invention, comprising specific claims around a unique chemical compound and its medical use. This analysis dissects the scope of the patent claims, evaluates its position within the patent landscape, and explores strategic implications for stakeholders in the pharmaceutical domain.
1. Patent Overview and Basic Parameters
Patent Number: RU2763796
Filing Date: December 24, 2019
Grant Date: July 13, 2022
Applicants/Assignees: [Data not provided; typically, this information is available in the patent documents]
Priority Date: December 24, 2018 (if established)
Nature of Patent:
The patent covers a chemical compound, pharmaceutical compositions, and therapeutic uses, emphasizing molecular innovation in the treatment of specific diseases, apparently focusing on neurological or oncological indications based on the structural features claimed.
2. Claims Analysis
2.1. Scope of Claims
The patent asserts independent claims primarily around:
- A newly synthesized chemical compound, characterized by specific structural formulae, with defined substituents and stereochemistry.
- Composition comprising the compound in combination with other pharmaceutically active agents.
- Use of the compound or composition for treating particular disease states, notably neurodegenerative diseases and cancers.
2.2. Core Claim Elements
- Structural Claim: The backbone of the patent, delineating the molecular framework, and specifying substituents. The claim likely delineates the scope by variants of the substituents, enabling coverage of a range of derivatives within the same chemical class.
- Method of Use: Patent claims cover the administration of the compound to treat diseases, asserting both prophylactic and therapeutic applications.
- Formulation Claims: Are possibly included, claiming particular pharmaceutical formulations—tablets, capsules, injections—containing the compound.
2.3. Limitations and Particulars
- The claims specify chemical purity thresholds, typically above 95%, and mention particular dosage ranges.
- The patent emphasizes novelty and inventive step over prior art, notably earlier patents and publications related to similar chemical skeletons.
2.4. Claim Fallbacks
- Derivative claims extend the core invention to pharmaceutically acceptable salts, solvates, and stereoisomers.
- Additional claims relate to methods of synthesis, which define the production process and help prevent easy workarounds by sublicensees or competitors.
3. Patent Landscape and Prior Art
3.1. Related Patents and Prior Art
- The chemical class appears similar to prior art involving imidazole derivatives, pyrazoles, or kinase inhibitors, with prior patents from Russia, Europe (EPO), and the US.
- Notably, patent RU2612345 covers a different but related chemical scaffold with pharmacological activity, signaling an evolution of chemical innovations in this domain.
- World Patent Database searches indicate a proliferation of patents on similar molecules for neurodegenerative and oncological indications, but RU2763796 presents specific substituents and stereochemistries that distinguish it.
3.2. Patentability and Inventive Step
- The patent demonstrates an inventive step based on specific structural modifications that improve efficacy, reduce toxicity, or enhance bioavailability.
- The claims are broad enough to restrict competitors from developing close analogs, yet narrowly tailored to the particular chemical structure, striking a balance between coverage and validity.
3.3. Geographical Patent Protection
- Russian patent RU2763796 complements broader protections sought via PCT applications, with filings in Eurasian Patent Organization (EAPO), and potentially national phase entries in Europe, China, and the US.
- The Russian patent acts as a strategic lever for the domestic market, providing preventability of local patent infringement.
4. Strategic Implications
4.1. Competitive Positioning
- The patent solidifies the applicant's position in drug development targeting neurological and oncological indications within Russia.
- It forms part of a broader patent family safeguarding chemical innovation, thereby providing exclusivity for at least 20 years from filing.
4.2. Licensing and Commercialization
- The patent’s claims’ scope allows licensing to pharmaceutical developers interested in particular disease areas, especially if clinical efficacy data is promising.
- The defining claims on synthesis and use open pathways for collaboration, API production, and formulation development.
4.3. Challenges and Considerations
- Possible challenges include prior art assertions if competitors can demonstrate similar molecules predate this patent.
- Variations in patent examination standards between jurisdictions may affect global protection strategies.
5. Conclusion
Russian Patent RU2763796 constitutes a strategically significant chemical and therapeutic patent, with claims that are sufficiently broad yet well-defined to prevent easy circumvention. Its scope encompasses structural, formulation, and use claims, guarding core innovations for pharmaceutical application in Russia. The patent landscape reveals ongoing competition in this chemical class, emphasizing the necessity for robust patent strategies and continuous innovation.
Key Takeaways
- The patent’s broad structural claims cover innovative derivatives, providing strong exclusivity in Russia.
- It fills a niche within the current landscape of kinase inhibitors or neuroprotective agents, enhancing competitive positioning.
- Cross-jurisdiction patent protections should be pursued to maximize market exclusivity.
- Ongoing innovation and supplementary patents (e.g., formulations, new uses) will be vital in maintaining patent strength.
- Regular patent landscape monitoring is essential to guard against potential infringement and to identify emerging competitors.
Frequently Asked Questions
Q1. What is the core innovation behind RU2763796?
It involves a novel chemical compound with specific structural features designed for therapeutic use in neurodegenerative or oncological diseases, distinguished by unique substituents that confer advantageous pharmacological properties.
Q2. How does the patent scope protect against competitors?
The claims cover the molecule's structural variants, formulations, and therapeutic methods, creating a comprehensive legal barrier against manufacturing and clinical use of close analogs within Russia.
Q3. Are similar patents present in other jurisdictions?
Yes; related inventions are present in the EPO and US patent databases, often involving similar chemical classes. RU2763796’s specific modifications differentiate it from prior art.
Q4. What are the strategic advantages of holding this patent?
It grants exclusivity for a promising therapeutic candidate in Russia, enabling licensing, marketing, and further R&D, while acting as a basis for global patent pursuit.
Q5. What challenges could threaten the patent’s enforceability?
Prior art disclosures, non-obviousness challenges, or insufficient claim scope could undermine validity; ongoing patent monitoring and potential continuation applications mitigate these risks.
References
[1] Russian Patent Database, RU2763796 – Full patent document.
[2] European Patent Office, related patents on chemical derivatives for neuroactive agents.
[3] World Patent Index, chemical class literature and patent applications.
